Evidence map›Paper›PMID 23171483›Full record

Trial reportTrials2012

Practice effects in a longitudinal, multi-center Alzheimer's disease prevention clinical trial.

Erin L Abner, Brandon C Dennis, Melissa J Mathews, Marta S Mendiondo, Allison Caban-Holt, Richard J Kryscio, Frederick A Schmitt, PREADViSE Investigators, John J Crowley, SELECT Investigators

Registry-linked trialOpen access · goldAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in Trials, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00040378 (Prevention of Alzheimer's Disease by Vitamin E and Selenium), which is not on this map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
10.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00040378 completednot on this map

Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)

TypeobservationalSponsorFrederick SchmittRan2002 to 2016Enrolled4,246ConditionsAlzheimer DiseaseArmsalphatocopherol, Selenium, Placebo replacement for vitamin E, Placebo replacement for Selenium
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 37 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Cognitive Decline in Alzheimer's Disease.Current topics in behavioral neurosciences · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Hippocampal Sclerosis of Aging Can Be Segmental: Two Cases and Review of the Literature.Journal of neuropathology and experimental neurology · 2015
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Erin L AbnerSanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA.
Brandon C Dennis
Melissa J Mathews
Marta S Mendiondo
Allison Caban-Holt
Richard J Kryscio
Frederick A Schmitt
PREADViSE Investigators
John J Crowley
SELECT Investigators
University of Kentucky · USCancer Research And Biostatistics · US

Funding

University of Kentucky Alzheimer's Disease Core Center - Biomarker CoreP30AG028383 · NIA · UNIVERSITY OF KENTUCKY · PI SCHMITT, FREDERICK · 2006 to 2020
$23.3M
Prevention of Alzheimer's Diseae by Vitamin E and SeleniumR01AG019241 · NIA · UNIVERSITY OF KENTUCKY · PI SCHMITT, FREDERICK · 2001 to 2012
$12.1M
NIA NIH HHS P30 AG028383NIA NIH HHS R01 AG019241
6 · The paper itself

Abstract

backgroundPractice effects are a known threat to reliability and validity in clinical trials. Few studies have investigated the potential influence of practice on repeated screening measures in longitudinal clinical trials with a focus on dementia prevention. The current study investigates whether practice effects exist on a screening measure commonly used in aging research, the Memory Impairment Screen (MIS).

methodsThe PREADViSE trial is a clinical intervention study evaluating the efficacy of vitamin E and selenium for Alzheimer's disease prevention. Participants are screened annually for incident dementia with the MIS. Participants with baseline and three consecutive follow-ups who made less than a perfect score at one or more assessments were included in the current analyses (N=1,803). An additional subset of participants with four consecutive assessments but who received the same version of the MIS at baseline and first follow-up (N=301) was also assessed to determine the effects of alternate forms on mitigating practice. We hypothesized that despite efforts to mitigate practice effects with alternate versions, MIS scores would improve with repeated screening. Linear mixed models were used to estimate mean MIS scores over time.

resultsAmong men with four visits and alternating MIS versions, although there is little evidence of a significant practice effect at the first follow-up, mean scores clearly improve at the second and third follow-ups for all but the oldest participants. Unlike those who received alternate versions, men given the same version at first follow-up show significant practice effects.

conclusionWhile increases in the overall means were small, they represent a significant number of men whose scores improved with repeated testing. Such improvements could bias case ascertainment if not taken into account.

Indexed as

Neuropsychological TestsAgedAged, 80 and overAlzheimer DiseaseAntioxidantsBiasCanadaChi-Square DistributionCognitionDrug Therapy, CombinationHumansIncidenceLinear ModelsLongitudinal StudiesMaleMemoryAntioxidantsSeleniumVitamin E

Identifiers

PMID23171483
PMCPMC3543284
OpenAlexW2141428346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.